Article Text

Download PDFPDF
Prognostic Factors in Women With Synchronous Endometrial and Ovarian Cancers
  1. Taejong Song, MD*,
  2. Seok Ju Seong, MD, PhD*,
  3. Duk-Soo Bae, MD, PhD,
  4. Jong-Hyeok Kim, MD, PhD,
  5. Dong Hoon Suh, MD, PhD§,
  6. Keun-Ho Lee, MD, PhD,
  7. Sang-Yoon Park, MD, PhD and
  8. Taek Sang Lee, MD, PhD#
  1. *Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University;
  2. Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine;
  3. Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul;
  4. §Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam;
  5. Department of Obstetrics and Gynecology, Seoul St Mary’s Hospital, Catholic University of Korea, Seoul;
  6. Gynecologic Cancer Branch and Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang; and
  7. #Department of Obstetrics and Gynecology, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea.
  1. Address correspondence and reprint requests to Seok Ju Seong, MD, PhD, Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, 566, Nonhyeon-ro, Gangnam-gu, Seoul 135-081, Republic of Korea. E-mail: sjseongcheil{at}


Objective The purpose of this study was to determine the prognostic factors in women with synchronous endometrial and ovarian cancers.

Methods Medical records of 3240 patients with endometrial cancer who had undergone primary surgery were collected from 7 institutions and were retrospectively reviewed. The progression-free survival (PFS) and overall survival (OS) curves and rates were calculated using the Kaplan-Meier method. Multivariate analysis to determine independent prognostic factors was performed using the Cox regression model.

Results The incidence of synchronous endometrial/ovarian cancer was 3.8% (123/3240 women). During the median follow-up period of 66 months, 33.3% and 26.1% of women developed recurrences and reported cancer-related deaths. The 5-year PFS and 5-year OS for all 123 women were 66.9% and 80.0%, respectively. In multivariate analysis, pretreatment CA-125 and tumor stage of the ovary showed prognostic significance about PFS (P = 0.043 and P = 0.027) and OS (P = 0.047 and P = 0.031), respectively.

Conclusions Pretreatment CA-125 and tumor stage of the ovary were independent prognostic factors for recurrence and survival.

  • Endometrial cancer
  • Ovarian cancer
  • Synchronous cancers
  • Prognostic factor

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.